David Lee Johnson is Chief Commercial Officer at Global Blood Therapeutics, Inc. (GBT). They have made 1 open-market trade across 1 company since 2026, most recently 2026-02-23.
CIK 0001733883
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GBT | 34,384 | $2.4M |
| VERA | 45,727 | $1.3M |
| Total | $3.6M |
Shares reported on the most recent Form 4, priced at the 2026-02-25 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERA | SELL | 2026-02-23 | 2026-02-25 | $41.98 | $108K | -5.5% | -5.8% | -16.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.